We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
Topics Covered
- Cellular localization of nuclear receptors
- Transcriptional activation and repression by NR
- Nuclear receptor complexes
- NR coregulators: coactivator and corepressor
- NR coregulators: different conformations
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Merk, D. (2025, May 29). Mechanisms and molecular function of nuclear receptors 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 23, 2025, from https://doi.org/10.69645/OFCC8607.Export Citation (RIS)
Publication History
- Published on May 29, 2025
Financial Disclosures
- Daniel Merk discloses affiliations with Ludwig-Maximilians-University Munich and the Free State of Bavaria. He is a member of the German Pharmaceutical Society (DPhG) and the German Chemical Society (GDCh). He has received honoraria for lectures, authoring, reviewing, and advisory activities from the DPhG, German Associations of Pharmacists, German Medical Association, Sanofi, Boehringer Ingelheim, ONO Pharmaceuticals, YS Life Science, AVOXA, SpringerNature, Wiley, and the Swiss National Science Foundation (SNF). Additionally, he holds five patents or patent applications related to nuclear receptor modulators and other small molecule drugs. His research is funded by the European Research Council (ERC), Innovative Medicines Initiative (IMI), German Research Foundation (DFG), German Federal Agency for Disruptive Innovation (SPRIN-D), and Immunic AG.
Mechanisms and molecular function of nuclear receptors 2
Published on May 29, 2025
7 min
Other Talks in the Series: Nuclear Receptors as Common Therapeutic Targets
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome everyone to Chapter 5 of
this short talk series on
nuclear receptors as
therapeutic targets.
In Chapter 5, we will
continue with the topic of
the structural and
molecular mechanisms
of nuclear receptor activity
and we will look at
transcriptional activation and
repression as well as
coregulator interactions.
0:22
We have seen in
previous chapters that
nuclear receptors differ in
their cellular localization.
Type I nuclear receptors
only translocate to
the nucleus and bind to DNA
after ligand binding,
as shown on the left.
Type II, III, and IV nuclear
receptors on the right
can bind to DNA in the absence
of ligands, and this has
consequences on their
effects on transcription.
0:47
When Type II, III, and
IV nuclear receptors
bind to DNA in the
absence of a ligand,
they typically recruit
corepressor complexes.
These corepressor complexes
containing, for example,
NCOR, which stands for
nuclear receptor corepressor,
on the one hand,
prevent the binding of
coactivators and
on the other hand,
often exhibit histone
deacetylase activity
leading to chromatin compaction.
Hence, corepressor
complexes recruited
to nuclear receptors inhibit
gene expression by
several mechanisms
meaning that many
nuclear receptors of
Type II, III, and IV,
which can bind to DNA
in unliganded state can cause
transcriptional repression.
In the activated state
shown here on the right,
the corepressor complex gets
replaced by a
coactivator complex.
These recruited
coactivators can mediate
histone acetylation and recruit
the transcriptional machinery
to activate transcription.
For many nuclear receptors,
this exchange of
corepressors by coactivators
happens in a
ligand-induced fashion,
and we will have a look at these
underlying mechanisms
in the next chapter.
Other Type II, III, and IV
nuclear receptors, for example,
retinoic acid receptor-related
orphan receptors
adopt the activated state with
bound coactivator complex
also in the absence
of ligands and
hence, constitutively
activate transcription
also without a ligand signal.
As indicated, the corepressor